Targeted drug delivery in pancreatic cancer |
| |
| Authors: | Xianjun Yu Yuqing Zhang Changyi Chen Qizhi Yao Min Li |
| |
| Affiliation: | 1. Michael E. DeBakey Department of Surgery, Molecular Surgeon Research Center, Elkins Pancreas Center, Baylor College of Medicine, One Baylor Plaza, Mail stop: BCM 391, Houston, TX 77030, USA;2. Pancreatic Disease Institute, Huashan Hospital, Fudan University, Shanghai, China |
| |
| Abstract: | Effective drug delivery in pancreatic cancer treatment remains a major challenge. Because of the high resistance to chemo and radiation therapy, the overall survival rate for pancreatic cancer is extremely low. Recent advances in drug delivery systems hold great promise for improving cancer therapy. Using liposomes, nanoparticles, and carbon nanotubes to deliver cancer drugs and other therapeutic agents such as siRNA, suicide gene, oncolytic virus, small molecule inhibitor, and antibody has been a success in recent preclinical trials. However, how to improve the specificity and stability of the delivered drug using ligand or antibody directed delivery represent a major problem. Therefore, developing novel, specific, tumor-targeted drug delivery systems is urgently needed for this terrible disease. This review summarizes the current progress on targeted drug delivery in pancreatic cancer and provides important information on potential therapeutic targets for pancreatic cancer treatment. |
| |
| Keywords: | Targeted drug delivery Pancreatic cancer |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
